POLI, DANIELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.224
EU - Europa 923
AS - Asia 152
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 4
AF - Africa 1
Totale 2.309
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.224
PL - Polonia 418
RU - Federazione Russa 206
SE - Svezia 73
IE - Irlanda 61
IT - Italia 51
SG - Singapore 41
HK - Hong Kong 35
CH - Svizzera 28
FI - Finlandia 26
CN - Cina 22
DE - Germania 19
TR - Turchia 19
GB - Regno Unito 16
JO - Giordania 16
BE - Belgio 12
VN - Vietnam 8
IN - India 6
AU - Australia 5
ES - Italia 4
EU - Europa 4
FR - Francia 4
ID - Indonesia 4
UA - Ucraina 3
CI - Costa d'Avorio 1
IR - Iran 1
NL - Olanda 1
PT - Portogallo 1
Totale 2.309
Salva come PNG Salva come JPEG
Città #
Warsaw 418
Santa Clara 372
Chandler 117
Fairfield 114
Ann Arbor 77
Cambridge 66
Ashburn 63
Dublin 61
Woodbridge 57
Seattle 45
Houston 43
Wilmington 39
Singapore 32
Bern 27
Hong Kong 24
Lawrence 23
Altamura 19
Izmir 19
Princeton 17
Buffalo 16
Jacksonville 15
Helsinki 14
Brussels 12
Boston 11
Boardman 10
Beijing 7
Dong Ket 6
Mumbai 6
San Diego 6
Shanghai 6
Medford 5
Barcelona 4
Cagliari 4
Jakarta 4
Norwalk 4
Redwood City 4
Genoa 3
Kent 3
Melbourne 3
Paris 3
Trieste 3
Andover 2
Bussolengo 2
Cardiff 2
Salerno 2
Verona 2
Yubileyny 2
Abidjan 1
Asciano 1
Bagno A Ripoli 1
Bremen 1
Castelfiorentino 1
Central District 1
Changsha 1
Chiswick 1
Città Della Pieve 1
Dearborn 1
Düsseldorf 1
Empoli 1
Guangzhou 1
Hangzhou 1
Hillsboro 1
Hounslow 1
London 1
Monash 1
Moscow 1
Munich 1
Phoenix 1
Poggibonsi 1
Rotterdam 1
Serravalle Pistoiese 1
Vaglia 1
Vila Nova De Gaia 1
Zurich 1
Totale 1.821
Salva come PNG Salva come JPEG
Nome #
The identification of the 2-phenylphthalazin-1(2H)-one scaffold as a new decorable core skeleton for the design of potent and selective human A3 adenosine receptor antagonists. 256
Sintesi e valutazione farmacologica di nuoviantagonisti dei recettori dell’adenosina 245
Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. 221
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a New Scaffold to obtain Potent and Selective Human A3 Adenosine Receptor Antagonists: New Insights into the Receptor-Antagonist Recognition† 144
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the prolong study 144
Synthesis and biological evaluation of a new set of pyrazolo[1,5-c]quinazolines as glycine/N-methyl-D-aspartic acid receptor antagonists 139
The APULEIO Study: an Italian, multicenter, prospective, observational experience evaluating the psychologic effects of Apixaban in the elderly 133
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the Prolong II prospective study 132
Fibrin resistance to lysis in patients with pulmonary hypertension other than thromboembolic. 126
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: Analysis of results obtained in the DULCIS study 117
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: A management study 116
Dodici contratti sociali per il parco agricolo multifunzionale 115
Sex, age and normal post-anticoagulation d-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the prolong study extension 111
OC-15 - Risk factors for cancer development after idiopathic venous thromboembolism 111
Novel potent and highly selective human A3 adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies 109
Pharmacological characterization of some selected 4,5-dihydro-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates and 3-hydroxyquinazoline-2,4-diones as (S)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propionic acid receptor antagonists. 105
Totale 2.324
Salva come PNG Salva come JPEG
Categoria #
all - tutte 5.782
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5.782
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020216 0 0 0 0 0 34 46 44 35 23 24 10
2020/2021242 19 29 12 24 11 32 17 17 20 30 6 25
2021/2022138 7 18 4 5 6 7 8 7 5 7 40 24
2022/2023387 29 84 12 30 40 52 43 14 44 3 7 29
2023/202488 4 14 12 6 12 4 5 25 2 0 3 1
2024/2025700 18 74 56 107 270 175 0 0 0 0 0 0
Totale 2.324